title: Structural analysis of CTLA-4 function in vivo.
abstract: CTLA-4-mediated inhibition of T cell activation may be accomplished by competition for ligands and/or by signals mediated through the intracellular domain. Studies have implicated Tyr201 in the cytoplasmic domain of CTLA-4 in regulating CTLA-4 signal transduction and intracellular trafficking. To investigate the mechanism of CTLA-4 function in vivo, transgenes encoding wild-type CTLA-4 (FL), a mutant lacking the cytoplasmic domain of CTLA-4 (DeltaCTLA-4 tail), or a CTLA-4 Tyr201 mutant (Y201V) were introduced into CTLA-4-deficient mice. CTLA-4-/- mice display an autoimmune lymphoproliferative disorder resulting in tissue destruction and early death. When either the FL or the Y201V transgene was bred into CTLA-4-/- animals, a complete rescue from lymphoproliferation and autoimmunity was observed. In contrast, CTLA-4-/- mice expressing the DeltaCTLA-4 tail transgene were long lived with no evidence of multiorgan lymphocytic infiltration, but exhibited lymphadenopathy and accumulated large numbers of activated T cells. Furthermore, these animals displayed a Th2-biased phenotype which conferred susceptibility to Leishmania infection. These results indicate that the inhibitory effect of CTLA-4 is mediated in part through the ability of the extracellular domain to compete for ligands. The cytoplasmic domain of CTLA-4, however, is required for complete inhibitory function of the receptor and for regulation of Th cell differentiation in vivo.
authors.affiliation: Gwen Knapp Center for Lupus and Immunology, University of Chicago, Chicago, IL 60637, USA. emastell@delphi.bsd.uchicago.edu
authors.forename: E L
authors.initials: EL
authors.lastname: Masteller
authors.forename: E
authors.initials: E
authors.lastname: Chuang
authors.forename: A C
authors.initials: AC
authors.lastname: Mullen
authors.forename: S L
authors.initials: SL
authors.lastname: Reiner
authors.forename: C B
authors.initials: CB
authors.lastname: Thompson
mesh_terms: D000069594:Abatacept; D000595:Amino Acid Sequence; D000818:Animals; D015703:Antigens, CD; D000943:Antigens, Differentiation / Q000096:biosynthesis / Q000737:chemistry* / Q000235:genetics / Q000502:physiology*; D060908:CTLA-4 Antigen; D003433:Crosses, Genetic; D005804:Genes, Lethal / Q000276:immunology; D020022:Genetic Predisposition to Disease; D006706:Homeostasis / Q000235:genetics / Q000276:immunology; D018796:Immunoconjugates; D016130:Immunophenotyping; D018320:Leishmania major / Q000276:immunology; D016773:Leishmaniasis, Cutaneous / Q000235:genetics / Q000276:immunology; D008206:Lymphatic Diseases / Q000276:immunology; D008213:Lymphocyte Activation / Q000235:genetics; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D008822:Mice, Transgenic; D008969:Molecular Sequence Data; D013163:Splenomegaly / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology / Q000473:pathology; D018418:Th2 Cells / Q000276:immunology / Q000378:metabolism; D019076:Transgenes / Q000276:immunology
chemical_list: D015703:Antigens, CD; D000943:Antigens, Differentiation; D060908:CTLA-4 Antigen; C556707:Ctla4 protein, mouse; D018796:Immunoconjugates; D000069594:Abatacept